Patents by Inventor Robert C. Malenka

Robert C. Malenka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240042206
    Abstract: The present invention provides, inter alia, methods, apparatus, and systems useful for ameliorating impulse control disorders known to be extremely disabling and common to many neurological and psychiatric conditions using closed-loop (responsive) neuro stimulation.
    Type: Application
    Filed: March 22, 2023
    Publication date: February 8, 2024
    Inventors: Casey Halpern, Robert C. Malenka, Hemmings Wu
  • Patent number: 11642528
    Abstract: The present invention provides, inter alia, methods, apparatus, and systems useful for ameliorating impulse control disorders known to be extremely disabling and common to many neurological and psychiatric conditions using closed-loop (responsive) neuro stimulation.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: May 9, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Casey Halpern, Robert C. Malenka, Hemmings Wu
  • Publication number: 20170202912
    Abstract: The present disclosure provides a method of inducing or modulating reward- or aversive-related behaviors in animals using light-responsive opsins. The present disclosure provides methods of identifying or screening compounds that may be used to treating mental disorders, or are relevant to disrupt or improve reward- or aversive related behaviors.
    Type: Application
    Filed: March 28, 2017
    Publication date: July 20, 2017
    Inventors: Stephan Lammel, ByungKook Lim, Robert C. Malenka
  • Patent number: 9636380
    Abstract: The present disclosure provides a method of inducing or modulating reward- or aversive-related behaviors in animals using light-responsive opsins. The present disclosure provides methods of identifying or screening compounds that may be used to treating mental disorders, or are relevant to disrupt or improve reward- or aversive related behaviors.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 2, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephan Lammel, ByungKook Lim, Robert C. Malenka
  • Publication number: 20140271479
    Abstract: The present disclosure provides a method of inducing or modulating reward- or aversive-related behaviors in animals using light-responsive opsins. The present disclosure provides methods of identifying or screening compounds that may be used to treating mental disorders, or are relevant to disrupt or improve reward- or aversive related behaviors.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephan Lammel, ByungKook Lim, Robert C. Malenka
  • Patent number: 7670838
    Abstract: Coupling of excitation to neurogenesis in proliferating post-natal NPCs is demonstrated in vitro and in vivo. Neurogenesis is potently enhanced by excitatory stimuli, and involves Cav1.2/1.3 channels and NMDA receptors. These Ca2+ influx pathways are located on the proliferating NPCs, allowing them to directly sense and process excitatory stimuli. Excitation increases the fraction of NPC progeny that are neurons, and increases total neuron number. Signaling in this pathway leads to rapid induction of a proneural gene expression pattern involving the bHLH genes HES1, Id2, and NeuroD, and the resulting cells become fully functional neurons defined by neuronal morphology, expression of neuronal structural proteins, expression of neuronal TTX-sensitive voltage gated Na+ channels, and synaptic incorporation into active neural circuits.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: March 2, 2010
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Robert C. Malenka
  • Publication number: 20080176963
    Abstract: Regulation of striatal indirect pathway endocannabinoid-mediated long-term depression (eCB-LTD) is used to improve motor deficits of striatal-based brain disorders. In such treatment, a dopamine D2 receptor agonist is administered in conjunction with an inhibitor of endocannabinoid degradation. In some embodiments, the inhibitor of endocannabinoid degradation is a fatty acid amine hydrolase inhibitor, or a monoacylglycerol lipase antagonist. The combination provides for a synergistic effect, with improved therapeutic effects. Also provided are kits and systems for practicing the subject methods, as well as methods of use of agents identified in the screening method of the invention.
    Type: Application
    Filed: January 22, 2008
    Publication date: July 24, 2008
    Inventors: Robert C. Malenka, Anatol Kreitzer